EU approves CSL Behring's Privigen for CIDP

04/8/2013 | Pharmaceutical Business Review Online

The European Commission granted CSL Behring approval to market Privigen, an intravenous immune globulin, as a treatment for chronic inflammatory demyelinating polyneuropathy. Positive results from the Privigen Impact on Mobility and Autonomy trial were cited in the application.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC